These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 31283942)

  • 1. Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study.
    Rossetti B; Baldin G; Sterrantino G; Rusconi S; De Vito A; Giacometti A; Gagliardini R; Colafigli M; Capetti A; d'Ettorre G; Celani L; Lagi F; Ciccullo A; De Luca A; Di Giambenedetto S; Madeddu G
    Antiviral Res; 2019 Sep; 169():104552. PubMed ID: 31283942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase-IV Non-interventional Study to Assess Virological Effectiveness, Safety, and Tolerability of DTG-based Antiretroviral Therapy in HIV-1 Infected Indian Persons Living with HIV.
    Ashta KK; Arora S; Khanna R; Raman N; Anilkumar A; Mohan C
    Curr HIV Res; 2024; 22(1):31-46. PubMed ID: 38284697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of Once/Day Dolutegravir Plus Boosted Darunavir as a Switch Strategy in Heavily Treated Patients with Human Immunodeficiency Virus.
    Navarro J; Santos JR; Silva A; Burgos J; Falcó V; Ribera E; Imaz A; Curran A
    Pharmacotherapy; 2019 Apr; 39(4):501-507. PubMed ID: 30723941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy, Convenience, Safety and Durability of DTG-Based Antiretroviral Therapies: Evidence from a Prospective Study by the Italian MaSTER Cohort.
    Fusco P; Nasta P; Quiros-Roldan E; Tondinelli A; Costa C; Fornabaio C; Mazzini N; Prosperi M; Torti C; Carosi G
    Viruses; 2023 Apr; 15(4):. PubMed ID: 37112904
    [No Abstract]   [Full Text] [Related]  

  • 5. Effectiveness, Safety, and Costs of Dolutegravir/Abacavir/Lamivudine Single-Tablet Regimen in a Real-Life Cohort of HIV-1 Adult Infected Patients.
    Rodriguez-Gonzalez CG; Chamorro-de-Vega E; Ortega-Navarro C; Alonso R; Herranz-Alonso A; Sanjurjo-Saez M
    Ann Pharmacother; 2020 Jul; 54(7):633-643. PubMed ID: 31910643
    [No Abstract]   [Full Text] [Related]  

  • 6. Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors or non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: A multicenter retrospective cohort study.
    Lagi F; Baldin G; Colafigli M; Capetti A; Madeddu G; Kiros ST; Di Giambenedetto S; Sterrantino G
    Int J Antimicrob Agents; 2019 Oct; 54(4):487-490. PubMed ID: 31195121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early clinical experience of dolutegravir in an HIV cohort in a larger teaching hospital.
    Todd S; Rafferty P; Walker E; Hunter M; Dinsmore WW; Donnelly CM; McCarty EJ; Quah SP; Emerson CR
    Int J STD AIDS; 2017 Oct; 28(11):1074-1081. PubMed ID: 28118801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort.
    Mondi A; Cozzi-Lepri A; Tavelli A; Rusconi S; Vichi F; Ceccherini-Silberstein F; Calcagno A; De Luca A; Maggiolo F; Marchetti G; Antinori A; d'Arminio Monforte A;
    J Int AIDS Soc; 2019 Jan; 22(1):e25227. PubMed ID: 30663278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients.
    Ciccullo A; Baldin G; Capetti A; Rusconi S; Sterrantino G; d'Ettorre G; Colafigli M; Modica S; Lagi F; Giacomelli A; Cossu MV; Restelli S; De Luca A; Di Giambenedetto S
    Antivir Ther; 2019; 24(1):63-67. PubMed ID: 30277466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
    Santevecchi BA; Miller S; Childs-Kean LM
    Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of dolutegravir plus lamivudine in treating HIV in China, including outcomes of patients coinfected with tuberculosis.
    Hou H; Ba H; Jin X; Luo P; Zhang Y; Li J; Jin J
    Medicine (Baltimore); 2024 Jul; 103(27):e38558. PubMed ID: 38968505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of dolutegravir + lamivudine q.d. with food in people with TB/HIV using a rifampicin-based regimen: A retrospective observational case series.
    Dou Y; Lu R; Su L; Lan K; Meng Z; Qin S; Huang L; Huang W; Xu Y; Lv Y; Wen Y; Lan S; Zuo Y; Zhang Y
    HIV Med; 2024 Jun; 25(6):754-758. PubMed ID: 38494173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective clinical study of dolutegravir- versus efavirenz-based regimen in treatment-naïve patients with advanced HIV infection in Nanjing, China.
    Zhong M; Li M; Qi M; Su Y; Yu N; Lv R; Ye Z; Zhang X; Xu X; Cheng C; Chen C; Wei H
    Front Immunol; 2022; 13():1033098. PubMed ID: 36700216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.
    Hidalgo-Tenorio C; Cortés LL; Gutiérrez A; Santos J; Omar M; Gálvez C; Sequera S; Jesús SE; Téllez F; Fernández E; García C; Pasquau J
    Medicine (Baltimore); 2019 Aug; 98(32):e16813. PubMed ID: 31393412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Foscarnet, zidovudine and dolutegravir combination efficacy and tolerability for late stage HIV salvage therapy: A case-series experience.
    Delory T; Papot E; Rioux C; Charpentier C; Auge-Courtoi C; Michard F; Peytavin G; Descamps D; Matheron S; Yazdanpanah Y
    J Med Virol; 2016 Jul; 88(7):1204-10. PubMed ID: 26636432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients.
    Curtis L; Nichols G; Stainsby C; Lim J; Aylott A; Wynne B; Clark A; Bloch M; Maechler G; Martin-Carpenter L; Raffi F; Min S
    HIV Clin Trials; 2014; 15(5):199-208. PubMed ID: 25350958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients.
    Radford M; Parks DC; Ferrante S; Punekar Y
    AIDS; 2019 Sep; 33(11):1739-1749. PubMed ID: 31180906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis.
    Snedecor SJ; Radford M; Kratochvil D; Grove R; Punekar YS
    BMC Infect Dis; 2019 May; 19(1):484. PubMed ID: 31146698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients.
    Baldin G; Ciccullo A; Rusconi S; Capetti A; Sterrantino G; Colafigli M; d'Ettorre G; Giacometti A; Cossu MV; Borghetti A; Gennari W; Mussini C; Borghi V; Di Giambenedetto S
    Int J Antimicrob Agents; 2019 Dec; 54(6):728-734. PubMed ID: 31521809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE).
    Ciccullo A; Baldin G; Capetti A; Borghi V; Sterrantino G; Latini A; Madeddu G; Celani L; Vignale F; Rossetti B; Dusina A; Cossu MV; Restelli S; Gennari W; Lagi F; Giacomelli A; Colafigli M; Brescini L; Borghetti A; Mussini C; Rusconi S; Di Giambenedetto S
    BMJ Open; 2019 Dec; 9(12):e029960. PubMed ID: 31796476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.